Kalispell Regional Medical Center
- Type
- Teaching hospital
- Where
- Kalispell, MT
- Medicare CCN
- 270051
- Received
- $726,269 in 362 records, 2020 ($80,209 general, $646,060 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Kalispell Regional Medical Center, Inc. Fuzzy (name and state)
- Business registration: Kalispell Regional Medical Center, Inc. Fuzzy (name and state)
- Business registration: KALISPELL REGIONAL MEDICAL CENTER, INC. Fuzzy (name and state)
- Business registration: KALISPELL REGIONAL MEDICAL CENTER, INC. Fuzzy (name and state)
- Nonprofit contractor: KALISPELL REGIONAL MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: KALISPELL REGIONAL MEDICAL CENTER INC Fuzzy (name and state)
- Lobbying client: KALISPELL REGIONAL MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: KALISPELL REGIONAL MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: KALISPELL REGIONAL MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: KALISPELL REGIONAL MEDICAL CENTER INC Fuzzy (name and state)
- Trademark owner: Kalispell Regional Medical Center, Inc. Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 76 | $80,209 |
| 2020 | Research payment | 286 | $646,060 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| ABBVIE INC. | 33 | $183,421 | 2020 |
| Eli Lilly and Company | 13 | $94,736 | 2020 |
| Novartis Pharmaceuticals Corporation | 4 | $91,758 | 2020 |
| Amgen Inc. | 9 | $87,299 | 2020 |
| CSL Behring | 22 | $38,940 | 2020 |
| Luminex Corporation | 1 | $37,278 | 2020 |
| Kowa Research Institute, Inc. | 13 | $34,741 | 2020 |
| SANOFI US SERVICES INC. | 12 | $33,124 | 2020 |
| PFIZER INC. | 7 | $20,881 | 2020 |
| Tandem Diabetes Care, Inc. | 51 | $16,600 | 2020 |
| BIOTRONIK INC. | 125 | $16,416 | 2020 |
| Incyte Corporation | 16 | $14,925 | 2020 |
| Stryker Corporation | 1 | $13,500 | 2020 |
| Esperion Therapeutics, Inc. | 27 | $12,081 | 2020 |
| Chiesi USA, Inc. | 6 | $10,306 | 2020 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $7,738 | 2020 |
| Medartis Inc. | 1 | $7,090 | 2020 |
| Sterilmed, Inc. | 12 | $2,485 | 2020 |
| AstraZeneca Pharmaceuticals LP | 1 | $1,200 | 2020 |
| Medtronic MiniMed, Inc. | 3 | $925 | 2020 |
| Ethicon Endo-Surgery Inc. | 1 | $624 | 2020 |
| Abbott Laboratories | 1 | $100 | 2020 |
| Zimmer Biomet Holdings, Inc. | 1 | $95 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 286 | $646,060 |
| Honoraria | 1 | $37,278 |
| Gift | 3 | $20,685 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 70 | $20,421 |
| Space rental or facility fees (teaching hospital only) | 1 | $1,200 |
| Education | 1 | $624 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Stryker Corporation | $13,500 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | Medartis Inc. | $7,090 | Gift (2 payments) | In-kind items and services | APTUS Device, ORTHO | 2020 | |
| 2020-12-31 | Zimmer Biomet Holdings, Inc. | $95 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2020 | |
| 2020-12-30 | ABBVIE INC. | $11,118 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M15-572 | 2020 |
| 2020-12-30 | ABBVIE INC. | $1,211 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M16-011 | 2020 |
| 2020-12-29 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-29 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-29 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-29 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-29 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-29 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-29 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-23 | Kowa Research Institute, Inc. | $1,315 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-12-22 | Esperion Therapeutics, Inc. | $667 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-22 | Esperion Therapeutics, Inc. | $667 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-22 | Esperion Therapeutics, Inc. | $667 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-22 | Esperion Therapeutics, Inc. | $667 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-22 | Esperion Therapeutics, Inc. | $667 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-22 | Esperion Therapeutics, Inc. | $667 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-22 | ABBVIE INC. | $450 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M15-572 | 2020 |
| 2020-12-22 | Esperion Therapeutics, Inc. | $407 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-22 | Esperion Therapeutics, Inc. | $238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-22 | Esperion Therapeutics, Inc. | $238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-12-21 | SANOFI US SERVICES INC. | $3,341 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2020 | |
| 2020-12-18 | Sterilmed, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-12-17 | Kowa Research Institute, Inc. | $1,704 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-12-17 | PFIZER INC. | $700 | Research payment | Cash or cash equivalent | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | PHASE 3B4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR TNF INHIBI | 2020 |
| 2020-12-16 | Incyte Corporation | $503 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-08 | Incyte Corporation | $57 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-08 | Incyte Corporation | $0 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-02 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-02 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-02 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-02 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-02 | Tandem Diabetes Care, Inc. | $200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-02 | Tandem Diabetes Care, Inc. | $200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-01 | Kowa Research Institute, Inc. | $2,892 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-12-01 | Amgen Inc. | $103 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | IMLYGIC Biological, Oncology | 2020 | |
| 2020-11-30 | ABBVIE INC. | $10,208 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M16-011 | 2020 |
| 2020-11-30 | ABBVIE INC. | $4,893 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M15-572 | 2020 |
| 2020-11-24 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-11-23 | SANOFI US SERVICES INC. | $8,110 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2020 | |
| 2020-11-19 | Eli Lilly and Company | $326 | Research payment | In-kind items and services | A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN | 2020 | |
| 2020-11-18 | Esperion Therapeutics, Inc. | $667 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-18 | Esperion Therapeutics, Inc. | $667 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-18 | Esperion Therapeutics, Inc. | $667 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-18 | Esperion Therapeutics, Inc. | $238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-18 | Esperion Therapeutics, Inc. | $238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-18 | Esperion Therapeutics, Inc. | $238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-18 | Esperion Therapeutics, Inc. | $238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-11-13 | Eli Lilly and Company | $18,718 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC L | 2020 | |
| 2020-11-12 | CSL Behring | $1,989 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-11-12 | CSL Behring | $50 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-11-12 | Sterilmed, Inc. | $46 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-11-11 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-11-11 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-11-09 | Medtronic MiniMed, Inc. | $375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $299 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $271 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $144 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $144 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $144 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $144 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $144 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-03 | BIOTRONIK INC. | $144 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-11-01 | Amgen Inc. | $103 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | IMLYGIC Biological, Oncology | 2020 | |
| 2020-10-29 | ABBVIE INC. | $7,360 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M16-011 | 2020 |
| 2020-10-29 | ABBVIE INC. | $1,613 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M15-998 | 2020 |
| 2020-10-28 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-28 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-28 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-27 | Kowa Research Institute, Inc. | $1,569 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-10-26 | SANOFI US SERVICES INC. | $3,244 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2020 | |
| 2020-10-20 | Esperion Therapeutics, Inc. | $667 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-10-20 | Esperion Therapeutics, Inc. | $667 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-10-20 | Esperion Therapeutics, Inc. | $238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-10-20 | Esperion Therapeutics, Inc. | $238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-10-14 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-14 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-14 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-14 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-14 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-13 | ABBVIE INC. | $450 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M15-572 | 2020 |
| 2020-10-07 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-10-07 | Sterilmed, Inc. | $104 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-10-02 | Ethicon Endo-Surgery Inc. | $624 | Education | In-kind items and services | CERTUS 140 MICROWAVE ABLATION SYSTEM Device, Interventional Solutions | 2020 | |
| 2020-10-01 | Novartis Pharmaceuticals Corporation | $8,500 | Research payment | Cash or cash equivalent | INC424J Drug | PHASE 3 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RUXOLITINI | 2020 |
| 2020-10-01 | Amgen Inc. | $103 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | IMLYGIC Biological, Oncology | 2020 | |
| 2020-09-30 | ABBVIE INC. | $2,149 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M16-011 | 2020 |
| 2020-09-30 | ABBVIE INC. | $1,995 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M15-998 | 2020 |
| 2020-09-28 | ABBVIE INC. | $13,842 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M15-572 | 2020 |
| 2020-09-28 | SANOFI US SERVICES INC. | $2,382 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2020 | |
| 2020-09-24 | Kowa Research Institute, Inc. | $3,855 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-09-18 | Esperion Therapeutics, Inc. | $667 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-18 | Esperion Therapeutics, Inc. | $407 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-18 | Esperion Therapeutics, Inc. | $407 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-18 | Esperion Therapeutics, Inc. | $238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-18 | Esperion Therapeutics, Inc. | $238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-18 | Esperion Therapeutics, Inc. | $238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-18 | Esperion Therapeutics, Inc. | $238 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2020 |
| 2020-09-16 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-09-16 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-09-10 | Chiesi USA, Inc. | $2,000 | Research payment | Cash or cash equivalent | CUSA-081-HEM-01 | 2020 | |
| 2020-09-10 | Chiesi USA, Inc. | $252 | Research payment | Cash or cash equivalent | CUSA-081-HEM-01 | 2020 | |
| 2020-09-10 | Chiesi USA, Inc. | $200 | Research payment | Cash or cash equivalent | CUSA-081-HEM-01 | 2020 | |
| 2020-09-10 | Chiesi USA, Inc. | $54 | Research payment | Cash or cash equivalent | CUSA-081-HEM-01 | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $256 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $193 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $186 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $84 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-09-09 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-09-08 | Eli Lilly and Company | $845 | Research payment | In-kind items and services | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC L | 2020 | |
| 2020-09-03 | Sterilmed, Inc. | $373 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-09-02 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-09-02 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-09-02 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-09-02 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-09-02 | Tandem Diabetes Care, Inc. | $150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-09-01 | Kowa Research Institute, Inc. | $1,381 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-08-28 | ABBVIE INC. | $9,199 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M16-011 | 2020 |
| 2020-08-28 | ABBVIE INC. | $1,287 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M15-998 | 2020 |
| 2020-08-24 | SANOFI US SERVICES INC. | $1,989 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2020 | |
| 2020-08-24 | ABBVIE INC. | $245 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M15-572 | 2020 |
| 2020-08-21 | Kowa Research Institute, Inc. | $450 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-08-18 | Medtronic MiniMed, Inc. | $100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2020 | |
| 2020-08-11 | CSL Behring | $1,567 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $235 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $235 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $235 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $235 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $235 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $193 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $90 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $90 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $90 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $90 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $90 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $54 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $54 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $54 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $54 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $54 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | CSL Behring | $50 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-11 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-08-05 | Sterilmed, Inc. | $263 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-08-05 | Sterilmed, Inc. | $63 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-08-04 | SANOFI US SERVICES INC. | $399 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2020 | |
| 2020-07-30 | ABBVIE INC. | $5,442 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M16-011 | 2020 |
| 2020-07-30 | ABBVIE INC. | $4,774 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M15-998 | 2020 |
| 2020-07-29 | ABBVIE INC. | $7,640 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M15-572 | 2020 |
| 2020-07-28 | Kowa Research Institute, Inc. | $3,963 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-07-22 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-07-22 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-07-22 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-07-22 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-07-22 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-07-22 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-07-21 | CSL Behring | $1,500 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-07-21 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-07-21 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-07-14 | BIOTRONIK INC. | $299 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-07-14 | BIOTRONIK INC. | $299 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-07-14 | BIOTRONIK INC. | $193 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-07-14 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-07-09 | CSL Behring | $150 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-07-09 | Incyte Corporation | $91 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-07-09 | Incyte Corporation | $87 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-07-09 | Incyte Corporation | $68 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-07-09 | Incyte Corporation | $2 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-07-08 | Novartis Pharmaceuticals Corporation | $938 | Research payment | In-kind items and services | EXJADE Drug, HEMATOLOGY | A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC | 2020 |
| 2020-07-08 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-07-02 | ABBVIE INC. | $7,484 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | M16-011 | 2020 |
| 2020-07-02 | PFIZER INC. | $1,575 | Research payment | Cash or cash equivalent | XELJANZ Drug, GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | PHASE 3B4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR TNF INHIBI | 2020 |
| 2020-07-02 | Kowa Research Institute, Inc. | $1,359 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-07-01 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-06-30 | ABBVIE INC. | $11,011 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M15-572 | 2020 |
| 2020-06-29 | SANOFI US SERVICES INC. | $798 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2020 | |
| 2020-06-29 | SANOFI US SERVICES INC. | $798 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatid | 2020 | |
| 2020-06-24 | Sterilmed, Inc. | $84 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 |
The latest 200 records of 362.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Kalispell, MT, county Flathead County, MT, state Montana; placed by its city name.
| Measure | Place (city or town) Kalispell, MT | County Flathead County, MT | State Montana |
|---|---|---|---|
| Population B01003 | 28,504 | 110,695 | 1,116,875 |
| Population, 2020 census P1 | 24,558 | 104,357 | 1,084,225 |
| Median age B01002 | 36.2 | 42.2 | 40.4 |
| Under 18 B01001 | 23.8% | 21.6% | 21.0% |
| 65 and over B01001 | 19.2% | 21.1% | 20.1% |
| Households B11001 | 11,795 | 44,233 | 458,859 |
| Foreign born B05002 | 3.5% | 2.8% | 2.3% |
| Median household income B19013 | $63,415 | $73,925 | $72,509 |
| Median family income B19113 | $89,279 | $93,578 | $92,794 |
| Per capita income B19301 | $36,679 | $41,557 | $41,711 |
| Poverty rate B17001 | 10.0% | 9.3% | 11.5% |
| Unemployment rate B23025 | 2.6% | 2.9% | 3.6% |
| Civilian labor force B23025 | 14,539 | 55,909 | 568,568 |
| Mean commute (minutes) B08013 | 14.9 | 19.6 | 19.1 |
| Bachelor's degree or higher B15003 | 34.8% | 37.2% | 35.2% |
| Housing units B25001 | 12,267 | 51,680 | 528,419 |
| Owner-occupied B25003 | 55.1% | 72.4% | 69.2% |
| Renters B25003 | 44.9% | 27.6% | 30.8% |
| Median home value B25077 | $428,000 | $535,500 | $375,800 |
| Median gross rent B25064 | $1,078 | $1,142 | $1,081 |
| White, not Hispanic B03002 | 87.4% | 90.0% | 83.6% |
| Black B03002 | 0.1% | 0.2% | 0.4% |
| Hispanic or Latino B03002 | 5.4% | 3.7% | 4.6% |
| Asian B03002 | 1.4% | 0.8% | 0.8% |
| American Indian and Alaska Native B03002 | 0.9% | 0.8% | 5.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Kalispell, MT.
Comments